celecoxib has been researched along with Carcinoma, Epidermoid in 87 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 7.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Pain is the most disruptive influence on the quality of prognosis among head and neck squamous cell carcinoma (HNSCC) patients." | 5.42 | The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. ( Chen, Z; Hu, R; Huang, Y; Jiang, H; Jiang, J; Xu, H; Yan, J; Yang, Y; Zhang, Y, 2015) |
| " We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity." | 3.80 | A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. ( Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G, 2014) |
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 3.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Eligible patients had head and neck cancers requiring palliative chemotherapy with ECOG PS 0-2 and adequate organ functions who could not afford cetuximab." | 2.80 | A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. ( Arya, S; Banavali, S; Bhattacharjee, A; Bhosale, B; D'Cruz, A; Dhumal, S; Joshi, A; Juvekar, S; Muddu, VK; Noronha, V; Patil, VM; Prabhash, K, 2015) |
| " We conducted a phase I and pharmacokinetic study with the erlotinib and celecoxib combination in patients with advanced premalignant lesions." | 2.79 | Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ( Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y, 2014) |
| "The combined treatment inhibited head and neck cancer cell growth significantly more potently than either single agent alone in cell line and xenograft models, and resulted in greater inhibition of cell-cycle progression at G1 phase than either single drug." | 2.78 | Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. ( Amin, AR; Beitler, JJ; Brandes, JC; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, WJ; Khuri, FR; Kono, S; Lewis, M; Moreno-Williams, R; Müller, S; Nannapaneni, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Thomas, SM; Zhang, H, 2013) |
| "Celecoxib was administered at escalating doses of 400, 600, and 800mg/day, starting 3days before the first fraction of radiotherapy and continuing throughout the course of radiotherapy." | 2.76 | Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. ( Bai, SM; Bi, ZF; Liu, YM; Luo, M; Wu, SK; Xue, WP, 2011) |
| " Phase II recommended dose of celecoxib combined with accelerated radiotherapy in advanced H&N cancer was 600mg bid." | 2.76 | Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. ( Cvek, J; Dusek, L; Feltl, D; Halamka, M; Horacek, J; Kominek, P; Kubes, J; Zavadova, E, 2011) |
| "Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE(2), after 12 weeks." | 2.73 | A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. ( Bertagnolli, MM; Dorfman, DM; Goguen, L; Haddad, RI; Krane, JF; Li, Y; Moran, AE; Norris, CM; Othus, M; Posner, MR; Wirth, LJ, 2008) |
| "Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy." | 2.73 | Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K, 2007) |
| "Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
| "Serum levels of squamous cell carcinoma antigen and the proliferative potential and subsets of peripheral T cells before and after celecoxib treatment were also analyzed." | 2.71 | Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. ( Battaglia, A; Ferrandina, G; Gessi, M; Lauriola, L; Legge, F; Navarra, P; Ranelletti, FO; Salutari, V; Scambia, G; Testa, AC; Tringali, G; Werner, U, 2003) |
| "Esophageal squamous cell carcinoma remains a leading cause of cancer death worldwide." | 2.71 | Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. ( Ahnen, DJ; Caldwell, KL; Dawsey, SM; Dong, Z; Giffen, CA; Hawk, ET; Korn, EL; Limburg, PJ; Lu, N; Ma, Y; Qiao, Y; Roth, MJ; Taylor, PR; Wang, G; Wei, W, 2005) |
| "Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years." | 2.71 | Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. ( Ansari, R; Fineberg, N; Fox, E; Govindan, R; Hanna, N; Helft, P; Kesler, K; Mantravadi, P; McLeod, H; Stoner, C, 2004) |
| "Incidence of cutaneous squamous cell carcinoma (cSCC) and actinic keratosis has increased worldwide, and non-steroidal anti-inflammatory drugs as celecoxib are considered for treatment." | 1.62 | High ROS Production by Celecoxib and Enhanced Sensitivity for Death Ligand-Induced Apoptosis in Cutaneous SCC Cell Lines. ( Eberle, J; May, S; Stockfleth, E; Ulrich, C; Zhu, J, 2021) |
| "Inflammation is closely related to neoplastic development and the release of inflammatory cytokines and chemokines represents a crucial event in this relationship." | 1.51 | Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma. ( Antunes, DM; Corrêa, L; DE Oliveira, APL; Duarte, CME; Fernandes, KPS; Guimarães, DM; Miguita, L; Nunes, FD; Rodrigues, MFSD, 2019) |
| "The celecoxib treatment decreased such rats to 0, 0, 0, and 13." | 1.51 | Effect of celecoxib on protein expression of FAK and Cx43 in DMBA induced rat tongue carcinoma cells. ( Guo, B; Li, YS; Shan, BZ; Sun, XF, 2019) |
| "Celecoxib is an inhibitor of cyclooxygenase-2, a gene that is often aberrantly expressed in the lung squamous cell carcinoma (LSQCC)." | 1.48 | Identification of key genes and long non‑coding RNAs in celecoxib‑treated lung squamous cell carcinoma cell line by RNA‑sequencing. ( Gan, C; Li, G; Luo, Q; Wang, X, 2018) |
| "Overexpression of cyclooxygenase-2 in oral cancer increases lymph node metastasis and is associated with a poor prognosis." | 1.46 | Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. ( Chang, PY; Chiang, SL; Chung, CM; Hua, CH; Ko, YC; Kuo, TM; Lin, SH; Tsai, MH; Velmurugan, BK; Wang, ZH; Yang, YH; Yeh, KT, 2017) |
| "Cotreatment with celecoxib and 5-FU partially blocked AKT phosphorylation, although no significant changes in total AKT protein levels were detected." | 1.46 | Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production. ( Ahn, SH; Choi, JJ; Kim, YH; Kwon, SK; Lee, DY; Oh, SM; Park, SW; Shin, ES; Sung, MW, 2017) |
| "Despite intensive investigation, oral squamous cell carcinomas (OSCC) represent a clinical challenge resulting in significant morbidity and mortality." | 1.42 | Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. ( Das, SK; Dash, R; Fisher, PB; Maji, S; Panda, S; Pattanaik, L; Pellecchia, M; Quinn, BA; Samal, SK; Sarkar, D, 2015) |
| "Pain is the most disruptive influence on the quality of prognosis among head and neck squamous cell carcinoma (HNSCC) patients." | 1.42 | The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. ( Chen, Z; Hu, R; Huang, Y; Jiang, H; Jiang, J; Xu, H; Yan, J; Yang, Y; Zhang, Y, 2015) |
| "Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15-30% of patients with BRAF(V600E) metastatic melanoma treated with BRAF inhibitors (BRAFi)." | 1.40 | COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. ( Atefi, M; Avramis, E; Cass, A; Cochran, AJ; Comin-Anduix, B; Escuin-Ordinas, H; Fu, Y; Graeber, TG; Herschman, HR; Huang, RR; Lo, RS; Marais, R; Ng, C; Ribas, A; Yashar, S, 2014) |
| "Celecoxib can inhibit proliferation and induce apoptosis in a dose- and time-dependent manner, repress telomerase activity, decrease hTERT mRNA and Bcl-2 protein expression and increase Bax protein expression, PGE2 had no effect on telomerase." | 1.40 | Antiproliferative effects of celecoxib in Hep-2 cells through telomerase inhibition and induction of apoptosis. ( Chen, XM; Fan, XL; Feng, HW; Jia, T; Xu, AT; Zhang, H; Zhang, HL; Zhao, YQ, 2014) |
| "Pretreatment with celecoxib inhibited nicotine-induced change in the expression of VEGF and COX-2." | 1.38 | Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer. ( Amanzadeh, A; Aslani, HR; Bidgoli, SA; Esfahani, M; Esfandiary, M; Ghahremani, MH; Habibzadeh, N; Salimi, M; Sedaghati, B, 2012) |
| " Dose-dependent cardiac toxicity limits long-term use of celecoxib, but it seems likely that this may be diminished by lowering its dose." | 1.36 | Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. ( Califano, JA; Fang, Y; Gu, X; Guo, Y; Hao, Y; Ji, H; Pang, X; Sha, W; Southerland, WM; Zhao, Y; Zhou, Y, 2010) |
| "Celecoxib could inhibit PGE2 production of Tca8113 cell in a dose-dependent manner, down-regulate MMP-2 secretion of Tca8113 cell, and at the same time significantly inhibit invasion and adhesion ability of these cells." | 1.36 | Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression. ( Huo, QJ; Li, WZ; Wang, XY; Xu, F, 2010) |
| "Oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide (NQO) show substantial overexpression of cyclooxygenase-2 (COX-2) when compared with adjacent phenotypically normal oral tissues." | 1.36 | Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. ( Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Phillips, JM; Steele, VE, 2010) |
| "Human tongue squamous cell carcinoma tumor cells Tca8113 and a mouse model with Tca8113 cells were used to study the growth inhibition of cisplatin enhanced by celecoxib." | 1.36 | Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro. ( Ding, YQ; Li, WZ; Li, ZG; Wang, XY; Zhang, JH, 2010) |
| "Celecoxib treatment for 24 h also resulted in significantly decreased adhesion of Tca8113 cells on Fn-coated surface in a dose-dependent manner." | 1.35 | [Inhibitory effects of COX-2 inhibitor on migration of human tongue squamous cell carcinoma Tca8113 cells]. ( Huo, QJ; Li, WZ, 2009) |
| "Celecoxib could notably enhance the inhibitory effect of bleomycin on Tca8113 cells by blocking cell cycle progress and thus resulting in the increasing G(0)/G(1) cells [(60." | 1.35 | [Celecoxib enhances the lethal effects of bleomycin in human tongue squamous carcinoma cell line Tca8113]. ( Ding, YQ; Li, WZ; Li, ZG; Wang, XY; Zhang, JH, 2009) |
| "Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide." | 1.35 | Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. ( Jalili, A; Karlhofer, FM; Pieczkowski, F; Pinc, A; Stingl, G; Wagner, SN, 2008) |
| "Esophageal and tongue cancers have both been associated with dietary zinc deficiency (ZD), and cyclooxygenase (COX-2) is often overexpressed in these cancers." | 1.33 | Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats. ( Farber, JL; Fong, LY; Jiang, Y; Zhang, L, 2005) |
| "Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) that is a critical factor in carcinogenesis, but precise mechanism of its action remains to be elucidated." | 1.33 | Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma. ( Kim, J; Kim, SH; Kwark, YE; Lee, EJ, 2006) |
| "In this study, we used an oral squamous cell carcinoma cell line to study growth inhibition and changes in critical cell cycle-regulating proteins induced by the selective COX-2 inhibitor celecoxib." | 1.32 | Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma. ( Chau, M; Gilbert, R; Jordan, RC; Lim, MS; Lim, S; Mäkitie, AA; Viani, MA, 2003) |
| "We used pairs of head and neck squamous cell carcinoma (HNSCC) cell lines derived from primary and metastatic tumors of the same patient to analyze eicosanoid metabolites by ESI-LC/MS/MS and COX/LOX expression by western immunoblotting." | 1.32 | Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. ( Lotan, R; Newman, RA; Schroeder, CP; Yang, P, 2004) |
| "Although all hamsters developed squamous cell carcinoma, the onset of tumor formation was delayed in a dose-dependent manner." | 1.32 | Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. ( Hashitani, S; Manno, Y; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2004) |
| "Celecoxib is a newly developed cyclo-oxygenase (COX)-2 inhibitor with significantly less toxicity." | 1.31 | Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. ( Fuentes, CF; Shapshay, SM; Wang, Z, 2002) |
| "The ratios of squamous cell carcinomas to papillomas and of sebaceous gland adenomas to papillomas plus squamous cell carcinomas were increased markedly in transgenic mice treated with DMBA alone compared with DMBA/phorbol 12-myristate 13-acetate-treated transgenic and wild-type mice." | 1.31 | Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. ( Berger, I; Furstenberger, G; Marks, F; Muller-Decker, K; Neufang, G; Neumann, M, 2002) |
| "Celecoxib-treated tumors showed reduced proliferation and increased apoptosis of both tumor and stromal cells compared with vehicle controls." | 1.31 | Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. ( Davis, TW; Masferrer, JL; Ornberg, RL; Zweifel, BS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.15) | 18.2507 |
| 2000's | 39 (44.83) | 29.6817 |
| 2010's | 43 (49.43) | 24.3611 |
| 2020's | 4 (4.60) | 2.80 |
| Authors | Studies |
|---|---|
| Kamal, MV | 1 |
| Rao, M | 1 |
| Damerla, RR | 1 |
| Pai, A | 1 |
| Sharan, K | 1 |
| Palod, A | 1 |
| Shetty, PS | 1 |
| Usman, N | 1 |
| Kumar, NAN | 1 |
| Shan, BZ | 1 |
| Guo, B | 1 |
| Li, YS | 2 |
| Sun, XF | 1 |
| Velmurugan, BK | 2 |
| Hua, CH | 2 |
| Tsai, MH | 2 |
| Lee, CP | 1 |
| Chung, CM | 2 |
| Ko, YC | 2 |
| Zhu, J | 1 |
| May, S | 1 |
| Ulrich, C | 1 |
| Stockfleth, E | 2 |
| Eberle, J | 2 |
| Gehrke, T | 1 |
| Scherzad, A | 1 |
| Hackenberg, S | 1 |
| Ickrath, P | 1 |
| Schendzielorz, P | 1 |
| Hagen, R | 1 |
| Kleinsasser, N | 1 |
| Chiang, SL | 1 |
| Lin, SH | 1 |
| Wang, ZH | 1 |
| Kuo, TM | 1 |
| Yeh, KT | 1 |
| Chang, PY | 1 |
| Yang, YH | 1 |
| Li, G | 1 |
| Wang, X | 2 |
| Luo, Q | 1 |
| Gan, C | 1 |
| Laquer, V | 1 |
| Dellinger, RW | 1 |
| Mannering, I | 1 |
| Garcia, AG | 1 |
| Abraham, V | 1 |
| Pavlis, J | 1 |
| Liu-Smith, F | 1 |
| De Feraudy, S | 1 |
| Meyskens, FL | 2 |
| Kelly, KM | 1 |
| Antunes, DM | 1 |
| Rodrigues, MFSD | 1 |
| Guimarães, DM | 1 |
| Duarte, CME | 1 |
| Miguita, L | 1 |
| Corrêa, L | 1 |
| DE Oliveira, APL | 1 |
| Fernandes, KPS | 1 |
| Nunes, FD | 1 |
| Reimer, A | 1 |
| Lu, S | 1 |
| He, Y | 1 |
| Bruckner-Tuderman, L | 1 |
| Technau-Hafsi, K | 1 |
| Meiss, F | 1 |
| Has, C | 1 |
| von Bubnoff, D | 1 |
| Shin, DM | 5 |
| Zhang, H | 2 |
| Saba, NF | 2 |
| Chen, AY | 2 |
| Nannapaneni, S | 2 |
| Amin, AR | 1 |
| Müller, S | 2 |
| Lewis, M | 2 |
| Sica, G | 2 |
| Kono, S | 1 |
| Brandes, JC | 1 |
| Grist, WJ | 1 |
| Moreno-Williams, R | 2 |
| Beitler, JJ | 2 |
| Thomas, SM | 1 |
| Chen, Z | 5 |
| Shin, HJ | 3 |
| Grandis, JR | 3 |
| Khuri, FR | 3 |
| Chen, ZG | 3 |
| Patil, V | 1 |
| Noronha, V | 2 |
| Krishna, V | 1 |
| Joshi, A | 2 |
| Prabhash, K | 2 |
| Abrahão, AC | 1 |
| Giudice, FS | 1 |
| Sperandio, FF | 1 |
| Pinto Junior, Ddos S | 1 |
| Hurwitz, SJ | 1 |
| Kono, SA | 1 |
| Yang, CS | 2 |
| Zhao, Y | 2 |
| Grist, W | 1 |
| Moore, CE | 1 |
| Owonikoko, TK | 1 |
| Ramalingam, S | 1 |
| Escuin-Ordinas, H | 1 |
| Atefi, M | 1 |
| Fu, Y | 1 |
| Cass, A | 1 |
| Ng, C | 1 |
| Huang, RR | 1 |
| Yashar, S | 1 |
| Comin-Anduix, B | 1 |
| Avramis, E | 1 |
| Cochran, AJ | 1 |
| Marais, R | 1 |
| Lo, RS | 1 |
| Graeber, TG | 1 |
| Herschman, HR | 1 |
| Ribas, A | 1 |
| Wirth, LJ | 3 |
| Yusup, G | 1 |
| Akutsu, Y | 1 |
| Mutallip, M | 1 |
| Qin, W | 1 |
| Hu, X | 1 |
| Komatsu-Akimoto, A | 1 |
| Hoshino, I | 1 |
| Hanari, N | 1 |
| Mori, M | 1 |
| Akanuma, N | 1 |
| Isozaki, Y | 1 |
| Matsubara, H | 1 |
| Sterzik, A | 1 |
| Paprottka, PM | 1 |
| Zengel, P | 1 |
| Hirner, H | 1 |
| Roßpunt, S | 1 |
| Eschbach, R | 1 |
| Moser, M | 1 |
| Havla, L | 1 |
| Ingrisch, M | 1 |
| Mack, B | 1 |
| Reiser, MF | 1 |
| Nikolaou, K | 1 |
| Cyran, CC | 1 |
| Zhao, YQ | 1 |
| Feng, HW | 1 |
| Jia, T | 1 |
| Chen, XM | 1 |
| Xu, AT | 1 |
| Zhang, HL | 1 |
| Fan, XL | 1 |
| Qian, M | 1 |
| Qian, D | 1 |
| Jing, H | 1 |
| Li, Y | 2 |
| Ma, C | 1 |
| Zhou, Y | 2 |
| Patil, VM | 1 |
| Muddu, VK | 1 |
| Dhumal, S | 1 |
| Bhosale, B | 1 |
| Arya, S | 1 |
| Juvekar, S | 1 |
| Banavali, S | 1 |
| D'Cruz, A | 1 |
| Bhattacharjee, A | 1 |
| Yang, Y | 1 |
| Yan, J | 1 |
| Huang, Y | 1 |
| Xu, H | 1 |
| Zhang, Y | 2 |
| Hu, R | 1 |
| Jiang, J | 1 |
| Jiang, H | 1 |
| Maji, S | 1 |
| Samal, SK | 1 |
| Pattanaik, L | 1 |
| Panda, S | 1 |
| Quinn, BA | 1 |
| Das, SK | 1 |
| Sarkar, D | 1 |
| Pellecchia, M | 1 |
| Fisher, PB | 1 |
| Dash, R | 1 |
| Lee, DY | 2 |
| Lim, JH | 1 |
| Kim, YJ | 1 |
| Kim, SD | 1 |
| Park, SW | 4 |
| Kwon, SK | 2 |
| Hah, JH | 1 |
| Kwon, TK | 1 |
| Kim, KH | 4 |
| Kim, YH | 2 |
| Sung, MW | 5 |
| Liu, JF | 1 |
| Drew, PA | 1 |
| Zhang, C | 1 |
| Oh, SM | 1 |
| Choi, JJ | 1 |
| Shin, ES | 1 |
| Ahn, SH | 1 |
| Jalili, A | 1 |
| Pinc, A | 1 |
| Pieczkowski, F | 1 |
| Karlhofer, FM | 1 |
| Stingl, G | 1 |
| Wagner, SN | 1 |
| Krane, JF | 1 |
| Othus, M | 1 |
| Moran, AE | 1 |
| Dorfman, DM | 1 |
| Norris, CM | 2 |
| Goguen, L | 1 |
| Posner, MR | 2 |
| Haddad, RI | 2 |
| Bertagnolli, MM | 1 |
| Li, WZ | 7 |
| Wang, XY | 6 |
| Ding, YQ | 4 |
| Li, ZG | 2 |
| Zhang, JH | 2 |
| Leem, DH | 1 |
| Choi, KH | 1 |
| Han, HS | 1 |
| Kim, JH | 1 |
| Shin, JA | 1 |
| Choi, ES | 1 |
| Shim, JH | 1 |
| Kong, G | 1 |
| Min, YK | 1 |
| Nam, JS | 1 |
| Oh, SH | 1 |
| Kim, KA | 1 |
| Kwon, KH | 1 |
| Cho, NP | 1 |
| Cho, SD | 1 |
| Huo, QJ | 3 |
| McCormick, DL | 1 |
| Phillips, JM | 1 |
| Horn, TL | 1 |
| Johnson, WD | 1 |
| Steele, VE | 2 |
| Lubet, RA | 2 |
| Hao, Y | 1 |
| Ji, H | 1 |
| Fang, Y | 1 |
| Guo, Y | 1 |
| Sha, W | 1 |
| Pang, X | 1 |
| Southerland, WM | 1 |
| Califano, JA | 1 |
| Gu, X | 1 |
| Ohtsu, N | 1 |
| Takaoka, K | 2 |
| Segawa, E | 1 |
| Hashitani, S | 2 |
| Noguchi, K | 2 |
| Kishimoto, H | 1 |
| Urade, M | 2 |
| Xu, F | 1 |
| Kim, HS | 1 |
| Hah, JW | 1 |
| Jeong, WJ | 1 |
| McLaren, CE | 1 |
| Elmets, CA | 1 |
| Viner, JL | 1 |
| Pentland, AP | 2 |
| Cantrell, W | 1 |
| Lin, HY | 1 |
| Bailey, H | 1 |
| Kang, S | 1 |
| Linden, KG | 1 |
| Heffernan, M | 1 |
| Duvic, M | 1 |
| Richmond, E | 1 |
| Elewski, BE | 1 |
| Umar, A | 1 |
| Bell, W | 1 |
| Gordon, GB | 1 |
| Yu, L | 1 |
| Chen, M | 1 |
| Li, Z | 1 |
| Wen, J | 1 |
| Fu, J | 1 |
| Guo, D | 1 |
| Jiang, Y | 3 |
| Wu, S | 1 |
| Cho, CH | 1 |
| Liu, S | 1 |
| Luo, WR | 1 |
| Li, LX | 1 |
| Li, SY | 1 |
| Jiang, HG | 1 |
| Chen, XY | 1 |
| Altorki, NK | 1 |
| Christos, P | 1 |
| Port, JL | 1 |
| Lee, PC | 1 |
| Mirza, F | 1 |
| Spinelli, C | 1 |
| Keresztes, R | 1 |
| Beneck, D | 1 |
| Paul, S | 1 |
| Stiles, BM | 1 |
| Schrump, DS | 1 |
| Halamka, M | 1 |
| Cvek, J | 1 |
| Kubes, J | 1 |
| Zavadova, E | 1 |
| Kominek, P | 1 |
| Horacek, J | 1 |
| Dusek, L | 1 |
| Feltl, D | 1 |
| Xue, WP | 1 |
| Bai, SM | 1 |
| Luo, M | 1 |
| Bi, ZF | 1 |
| Liu, YM | 1 |
| Wu, SK | 1 |
| Edelman, MJ | 1 |
| Hodgson, L | 1 |
| Christenson, R | 1 |
| Jewell, S | 1 |
| Vokes, E | 1 |
| Kratzke, R | 1 |
| Rodust, PM | 1 |
| Fecker, LF | 1 |
| Doll, CM | 1 |
| Winter, K | 3 |
| Gaffney, DK | 3 |
| Ryu, JK | 1 |
| Jhingran, A | 1 |
| Dicker, AP | 3 |
| Weidhaas, JB | 1 |
| Miller, BE | 1 |
| Magliocco, AM | 1 |
| Liebman, TN | 1 |
| Stein, JA | 1 |
| Polsky, D | 1 |
| Salimi, M | 1 |
| Esfahani, M | 1 |
| Habibzadeh, N | 1 |
| Aslani, HR | 1 |
| Amanzadeh, A | 1 |
| Esfandiary, M | 1 |
| Sedaghati, B | 1 |
| Bidgoli, SA | 1 |
| Ghahremani, MH | 1 |
| Wang, Z | 3 |
| Fuentes, CF | 2 |
| Shapshay, SM | 2 |
| Muller-Decker, K | 1 |
| Neufang, G | 1 |
| Berger, I | 1 |
| Neumann, M | 1 |
| Marks, F | 1 |
| Furstenberger, G | 1 |
| Zweifel, BS | 1 |
| Davis, TW | 1 |
| Ornberg, RL | 1 |
| Masferrer, JL | 2 |
| Mohan, S | 1 |
| Epstein, JB | 1 |
| Ferrandina, G | 1 |
| Ranelletti, FO | 1 |
| Legge, F | 1 |
| Lauriola, L | 1 |
| Salutari, V | 1 |
| Gessi, M | 1 |
| Testa, AC | 1 |
| Werner, U | 1 |
| Navarra, P | 1 |
| Tringali, G | 1 |
| Battaglia, A | 1 |
| Scambia, G | 1 |
| Mäkitie, AA | 1 |
| Chau, M | 1 |
| Lim, S | 1 |
| Viani, MA | 1 |
| Gilbert, R | 1 |
| Lim, MS | 1 |
| Jordan, RC | 1 |
| Terakado, N | 1 |
| Shintani, S | 1 |
| Yano, J | 1 |
| Chunnan, L | 1 |
| Mihara, M | 1 |
| Nakashiro, K | 1 |
| Hamakawa, H | 1 |
| Roh, JL | 2 |
| Heo, DS | 1 |
| Lee, DW | 1 |
| Chen, PY | 1 |
| Long, QC | 1 |
| Schroeder, CP | 1 |
| Yang, P | 1 |
| Newman, RA | 1 |
| Lotan, R | 1 |
| Zhang, X | 3 |
| Li, M | 1 |
| Wieand, HS | 2 |
| Nishimura, N | 1 |
| Manno, Y | 1 |
| Sakurai, K | 1 |
| Fong, LY | 2 |
| Zhang, L | 1 |
| Farber, JL | 2 |
| Govindan, R | 1 |
| McLeod, H | 1 |
| Mantravadi, P | 1 |
| Fineberg, N | 1 |
| Helft, P | 1 |
| Kesler, K | 1 |
| Hanna, N | 2 |
| Stoner, C | 1 |
| Ansari, R | 1 |
| Fox, E | 1 |
| Li, N | 1 |
| Sood, S | 1 |
| Wang, S | 1 |
| Fang, M | 1 |
| Wang, P | 1 |
| Sun, Z | 1 |
| Chen, X | 1 |
| Graepler, F | 1 |
| Gregor, M | 1 |
| Lauer, UM | 1 |
| Park, K | 1 |
| Yang, JH | 1 |
| Choi, Y | 1 |
| Lee, C | 1 |
| Kim, SY | 1 |
| Byun, Y | 1 |
| Limburg, PJ | 2 |
| Wei, W | 1 |
| Ahnen, DJ | 1 |
| Qiao, Y | 1 |
| Hawk, ET | 2 |
| Wang, G | 2 |
| Giffen, CA | 1 |
| Roth, MJ | 1 |
| Lu, N | 1 |
| Korn, EL | 1 |
| Ma, Y | 1 |
| Caldwell, KL | 1 |
| Dong, Z | 1 |
| Taylor, PR | 2 |
| Dawsey, SM | 2 |
| Lippman, SM | 1 |
| Gibson, N | 1 |
| Subbaramaiah, K | 1 |
| Dannenberg, AJ | 1 |
| Choe, MS | 2 |
| Lin, Y | 1 |
| Sun, SY | 1 |
| Chen, A | 1 |
| Lindeman, NI | 1 |
| Zhao, X | 1 |
| Lee, JC | 1 |
| Joshi, VA | 1 |
| Joshi, N | 1 |
| Johnson, LL | 1 |
| Wei, WQ | 1 |
| Abnet, CC | 1 |
| Dong, ZW | 1 |
| Qiao, YL | 1 |
| Kirsch, IR | 1 |
| Lee, EJ | 2 |
| Kim, SH | 1 |
| Kwark, YE | 1 |
| Kim, J | 2 |
| Miller, B | 2 |
| Eifel, PJ | 2 |
| Ryu, J | 2 |
| Avizonis, V | 2 |
| Fromm, M | 2 |
| Greven, K | 2 |
| Kwak, YE | 1 |
| Jeon, NK | 1 |
| Bock, JM | 1 |
| Menon, SG | 1 |
| Sinclair, LL | 1 |
| Bedford, NS | 1 |
| Goswami, PC | 1 |
| Domann, FE | 1 |
| Trask, DK | 1 |
| Small, W | 1 |
| Klass, CM | 1 |
| Scheper, MA | 1 |
| Nikitakis, NG | 1 |
| Sauk, JJ | 1 |
| Riley, M | 1 |
| Liu, X | 1 |
| Smalley, KJ | 1 |
| Guttridge, DC | 1 |
| Agarwala, A | 1 |
| Fisher, W | 1 |
| Bruetman, D | 1 |
| McClean, J | 1 |
| Taber, D | 1 |
| Titzer, M | 1 |
| Juliar, B | 1 |
| Yu, M | 1 |
| Breen, T | 1 |
| Einhorn, LH | 1 |
| Schoggins, JW | 1 |
| Scott, GA | 1 |
| Khan, KN | 1 |
| Han, R | 1 |
| Grubbs, CJ | 1 |
| Koki, AT | 1 |
| Leahy, KM | 1 |
| Kelloff, GJ | 1 |
| Hill, DL | 1 |
| Seibert, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Chemoprevention With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Premalignant Lesions of Head and Neck of Former Smokers[NCT00314262] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses[NCT00027976] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2001-12-31 | Withdrawn | ||
| Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention[NCT01192204] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response evaluation was based on pathologic examination of the degree of dysplasia observed and recorded by an expert head and neck pathologist. Pathologic complete response was defined as complete disappearance of dysplasia from the epithelium. Pathologic partial response was defined as improvement of dysplasia by at least one degree (i.e., severe dysplasia becomes moderate dysplasia). Pathologic minor response or stable disease was defined as minor focal improvement without change of degree of dysplasia (i.e., focal improvement from moderate to mild dysplasia with still moderate dysplasia overall) or no pathologic changes after treatment. Pathologic progressive disease was defined as worsening by at least one degree of dysplasia (i.e., mild to moderate dysplasia) or development of invasive cancer on or following treatment. (NCT00314262)
Timeframe: 12 months from time of enrollment
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete remission (CR) | Partial remission (PR) | Progressive disease (PD) | Stable disease (SDi) | |
| Erlotinib & Celecoxib | 3 | 1 | 1 | 2 |
Response evaluation was based on pathologic examination of the degree of dysplasia observed and recorded by an expert head and neck pathologist. Pathologic complete response was defined as complete disappearance of dysplasia from the epithelium. Pathologic partial response was defined as improvement of dysplasia by at least one degree (i.e., severe dysplasia becomes moderate dysplasia). Pathologic minor response or stable disease was defined as minor focal improvement without change of degree of dysplasia (i.e., focal improvement from moderate to mild dysplasia with still moderate dysplasia overall) or no pathologic changes after treatment. Pathologic progressive disease was defined as worsening by at least one degree of dysplasia (i.e., mild to moderate dysplasia) or development of invasive cancer on or following treatment. (NCT00314262)
Timeframe: Up to 55 months from initiation of therapy. Median duration of follow-up was 36 months.
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Stage I invasive carcinoma | Stage II oral cavity carcinoma | Invasive squamous cell carcinoma | Recurrent moderate dysplasia | Recurrent severe dysplasia | Recurrent high-grade dysplasia | Complete remission | |
| Erlotinib & Celecoxib | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Participants received a fixed dose of celecoxib 400 mg orally BID continuously for 6 months. Erlotinib was dose escalated at 3 dose levels of 50, 75, and 100 mg orally every day for 6 months. Dose escalation followed a standard 3+3 escalation design. (NCT00314262)
Timeframe: 12 months from time of enrollment
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal cramping, Grade 1 | Alopecia, Grade 1 | Anemia, Grade 1 | Anemia, Grade 2 | Anxiety, Grade 1 | Decreased protein, Grade 1 | Leukopenia, Grade 1 | Leukopenia, Grade 2 | Depression, Grade 1 | Diarrhea, Grade 1 | Dry eyes, Grade 1 | Dry skin, Grade 1 | Elevated LDH, Grade 1 | Elevated serum creatinine, Grade 1 | Elevated serum creatinine, Grade 2 | Elevated alkaline phosphatase, Grade 1 | Elevated ALT, Grade 1 | Elevated AST, Grade 4 | Fatigue, Grade 1 | Hyperbilirubinemia, Grade 1 | Hypercholesterolemia, Grade 1 | Hyperglycemia, Grade 1 | Hyperglycemia, Grade 2 | Hypoalbuminemia, Grade 1 | Hypoalbuminemia, Grade 2 | Hypocalcemia, Grade 1 | Hypoglycemia, Grade 1 | Hypoglycemia, Grade 2 | Hypokalemia, Grade 1 | Hyponatremia, Grade 1 | Mouth sores, Grade 1 | Mouth sores, Grade 2 | Mucositis, Grade 1 | Mucositis, Grade 3 | Nausea, Grade 1 | Neuropathy, Grade 1 | Pruritis, Grade 1 | Rash, Grade 1 | Rash, Grade 3 | Shortness of breath, Grade 1 | Strep throat, Grade 2 | Urosepsis, Grade 3 | Vomiting, Grade 1 | |
| Erlotinib & Celecoxib | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 3 | 5 | 4 | 6 | 3 | 4 | 1 | 3 | 5 | 4 | 6 | 2 | 2 | 7 | 2 | 3 | 1 | 4 | 1 | 1 | 2 | 3 | 9 | 3 | 3 | 1 | 4 | 3 | 2 | 8 | 2 | 3 | 1 | 1 | 2 |
The remaining oral dysplasia lesion will be inspected at each follow up appointment (every 10-14 days). Biopsies will be immediately conducted on patients with any indication of malignant transformation including indurated, rolled borders, nonhealing ulcers, etc. Accordingly, these patients will withdraw from the trial. Participants will also be monitored for any changes consistent with contact mucositis e.g. soreness and erythema at application site. Clinical photographs were taken for the patients records. Pre treatment and post treatment photographs, with a ruler in place, were used for accurate pre and post treatment size measurement. NOTE: if treatment is beneficial, lesional size will decrease which will be reflected as a negative number. (NCT01192204)
Timeframe: pretreatment and posttreatment (3 months treatment duration)
| Intervention | mm^2 (Mean) |
|---|---|
| 10% FBR Gel | -26.12 |
| Placebo Gel | 18.12 |
Laboratory experiments will be conducted to assess the effects of gel treatment on pre and post loss of heterozygosity (LOH) events at loci associated with tumor suppressor genes. (NCT01192204)
Timeframe: Before and after the 3 month treatment duration
| Intervention | LOH events (Mean) |
|---|---|
| 10% FBR Gel | 0.9 |
| Placebo Gel | 0.4 |
A hemisection of lesional tissue will be conducted before the 3 month treatment to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. Anl excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment to provide a posttreatment diagnosis. The 0 to 8 histologic scale was:0=normal with or without hyperkeratosis BEST OUTCOME, 1=atypia, 2=mild dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia,5=moderate-severe dysplasia,6=severe dysplasia, 7=carcinoma in situ, 8=invasive oral squamous cell carcinoma (WORST OUTCOME). (NCT01192204)
Timeframe: Before and after the 3 month treatment.
| Intervention | unit on histologic grade scale (Mean) | |
|---|---|---|
| Pretreatment | Posttreatment | |
| 10% FBR Gel | 2.36 | 1.9 |
| Placebo Gel | 2.83 | 2.58 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
3 reviews available for celecoxib and Carcinoma, Epidermoid
| Article | Year |
|---|---|
A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Head and Neck N | 2023 |
Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous | 2003 |
[Anti-angiogenic therapy for gastrointestinal tumours].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2005 |
18 trials available for celecoxib and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Sq | 2013 |
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Ant | 2015 |
The effect of celecoxib on DNA methylation of CDH13, TFPI2, and FSTL1 in squamous cell carcinoma of the esophagus in vivo.
Topics: Adult; Aged; Cadherins; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; DNA Methyl | 2016 |
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase | 2008 |
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous | 2010 |
Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; | 2011 |
Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Clinical Trials, Phase II as Topic; Combined Modal | 2011 |
Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibi | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arac | 2011 |
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antigens, Neoplasm; Apoptosis; Blood Vessels; Carcinoma, Sq | 2003 |
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2004 |
Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.
Topics: Adult; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Carcinoma, Squamous | 2005 |
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2005 |
Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population.
Topics: Carcinoma, Squamous Cell; Celecoxib; China; Disease Progression; Double-Blind Method; Esophageal Neo | 2006 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2007 |
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
66 other studies available for celecoxib and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Effect of celecoxib on protein expression of FAK and Cx43 in DMBA induced rat tongue carcinoma cells.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxi | 2019 |
Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells.
Topics: Cadherins; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2020 |
High ROS Production by Celecoxib and Enhanced Sensitivity for Death Ligand-Induced Apoptosis in Cutaneous SCC Cell Lines.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Caspases; Celecoxib; Cell Death; | 2021 |
Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell | 2017 |
Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma.
Topics: Adolescent; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Squamous | 2017 |
Identification of key genes and long non‑coding RNAs in celecoxib‑treated lung squamous cell carcinoma cell line by RNA‑sequencing.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; High- | 2018 |
12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinoma.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Biopsy; Carcinoma, Squamous Cell; Celecoxib; Chemopreven | 2018 |
Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tu | 2019 |
Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; C | 2020 |
Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2013 |
Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Cultu | 2013 |
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; | 2014 |
Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention | 2014 |
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C | 2014 |
DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Celecoxib; Combined M | 2015 |
Antiproliferative effects of celecoxib in Hep-2 cells through telomerase inhibition and induction of apoptosis.
Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation; Cyclooxygenas | 2014 |
Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Ce | 2014 |
The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Survival; Cetuxim | 2015 |
Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Topics: 4-Nitroquinoline-1-oxide; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Prote | 2015 |
Effect of Celecoxib on Survival of Mobile Tongue Cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival | 2015 |
Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Celeco | 2017 |
Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2008 |
[Effects of celecoxib on PGE2 synthesis and COX-2 and VEGF-C mRNA expression in Tca8113 cell lines].
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2009 |
[Celecoxib enhances the lethal effects of bleomycin in human tongue squamous carcinoma cell line Tca8113].
Topics: Apoptosis; Bleomycin; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygen | 2009 |
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation | 2010 |
[Inhibitory effects of COX-2 inhibitor on migration of human tongue squamous cell carcinoma Tca8113 cells].
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; H | 2009 |
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Gene Expr | 2010 |
Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell L | 2010 |
[Celecoxib induces cell cycle arrest and apoptosis in human tongue squamous carcinoma cell line Tca8113].
Topics: Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2 Inhib | 2010 |
Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2010 |
Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenas | 2010 |
Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygena | 2010 |
Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cy | 2010 |
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?
Topics: Adenoma; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; | 2010 |
Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cispla | 2011 |
[Influence of celecoxib on invasiveness of human high-metastatic nasopharyngeal carcinoma cell line CNE-2Z].
Topics: Apoptosis; Cadherins; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Gen | 2010 |
[Effect of cyclooxygenase-2 inhibitor on expression of matrix metalloproteinase-2 and invasion of tongue squamous cell carcinoma cell line Tca8113].
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; H | 2010 |
Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w.
Topics: Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; C | 2012 |
COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinica | 2013 |
Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenas | 2012 |
Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Celecoxib; Cell Di | 2002 |
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenoma; Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib | 2002 |
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Ce | 2002 |
Cancer "photo-chemoprevention" with pulsed dye laser and celecoxib.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Combined Modality Therapy; Disease Mo | 2003 |
Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Surviva | 2003 |
Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; | 2004 |
Celecoxib can prevent tumor growth and distant metastasis in postoperative setting.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Cell Line, Tumor | 2004 |
Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Celeco | 2004 |
Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Dose-Response Re | 2004 |
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase | 2004 |
Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; C | 2004 |
Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Topics: 4-Nitroquinoline-1-oxide; Animals; Apoptosis; Blotting, Western; Carcinogens; Carcinoma, Squamous Ce | 2005 |
Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Carcinoma, Squamous Cell; Celecoxib; Ce | 2005 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogen | 2005 |
Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyc | 2005 |
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenas | 2005 |
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenas | 2005 |
Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma.
Topics: Actins; Aged; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; | 2006 |
The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibito | 2007 |
Celecoxib toxicity is cell cycle phase specific.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Growth Processes; Cyclin-Dependent Kin | 2007 |
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumo | 2007 |
Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Ce | 2007 |
Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.
Topics: Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2008 |
Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 1999 |
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Squamous Cel | 2000 |